Omega Therapeutics (NASDAQ:OMGA – Free Report) had its target price trimmed by Chardan Capital from $12.00 to $7.00 in a research report released on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the stock. Chardan Capital also issued estimates for Omega Therapeutics’ FY2024 earnings at ($1.31) EPS. Separately, Wedbush reissued an […]